Immunoglobulin A Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)

Immunoglobulin A nephropathy (IgAN), or Berger’s disease, is an autoimmune disease that causes galactose-deficient IgA1 (Gd-IgA1) to accumulate in the kidney glomeruli, impairing their blood filtration function. Supportive care for IgAN, such RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and diuretics, plays a major role in slowing the disease’s progression. Calliditas Therapeutics’ Tarpeyo / Kinpeygo (delayed-release budesonide) and Travere Therapeutics’ Filspari (sparsentan) are approved to treat IgAN. Over the 2023-2033 forecast period, the IgAN therapy market will experience significant growth owing to the emergence of novel therapeutic pathways, such as complement factor B inhibition (e.g., Novartis’s Fabhalta [iptacopan], Roche’s RO7434656), APRIL and/or BAFF inhibition (e.g., Otsuka’s sibeprenlimab, Novartis’s zigakibart, Vera Therapeutics’ atacicept), and angiotensin and/or endothelin receptor antagonism (e.g., Novartis’s atrasentan). Supported by insights from thought leaders, we analyze the challenges and opportunities treating this complex disease.

Questions answered

• What percentage of the IgAN population receive drug treatment? How do physicians use current therapies to treat the disease?
• Where will Tarpeyo / Kinpeygo and Filspari (sparsentan) be positioned in the evolving IgAN treatment landscape? Which emerging therapies do experts find most promising, and how will they influence future prescribing patterns?
• Which unmet needs will the emerging therapies be able to fulfill?
• What access and reimbursement challenges are the emerging therapies anticipated to face upon market entry?

SCOPE

• Geography: United States, France, Germany, Italy, Spain, United Kingdom, and Japan
• Primary research: 19 country-specific interviews with thought-leading nephrologists. Supported by survey data collected for this and other Clarivate research
• Epidemiology: Diagnosed prevalent and drug-treated cases of IgA nephropathy by country and age groups
• Forecast: 10-year, annualized, drug-level sales and patient share of key IgA nephropathy therapies through 2033, segmented by brands / generics and epidemiological subpopulations
• Emerging therapies: Phase 3/PR: 6 drugs; Phase 2: 7 drugs; coverage of select early-phase products

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.